1 / 39

Clearance of the Cardiac Patient for Non-cardiac Surgery

Clearance of the Cardiac Patient for Non-cardiac Surgery. Evaluation and Management. PRE-OP CLEARANCE. Not truly “Clearance” – but assurance that the pt.’s condition is optimal for the proposed surgery in the planned time frame.

brit
Download Presentation

Clearance of the Cardiac Patient for Non-cardiac Surgery

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Clearance of the Cardiac Patient for Non-cardiac Surgery Evaluation and Management

  2. PRE-OP CLEARANCE • Not truly “Clearance” – but assurance that the pt.’s condition is optimal for the proposed surgery in the planned time frame. • A focused assessment, addressing a particular issue specified by the parties: Cardiac risk? Atr. Fib? CHF? Pulmonary risk? General medical status? What is consultant’s role here? • A calculation of the relative risk and estimation of the Risk/Benefit. Controversial issues best communicated verbally.

  3. PRE-OP CLEARNCE –IITHE NOTE • List of the medical/cardiac problems, severity, and degree of control. • List of medications. Allergies. • Steps to achieve optimal pre-op status- Tests (minimal) and treatments, e.g., A/C Rx, CHF, BB’s. • Peri-op precautions, e.g., prophylactic Abx, volume guidelines. Post-op monitoring steps. • One page! Concise! LEGIBLE! Clearly signed, with Tel./Beeper No.

  4. COMPOSITEQUALITATIVE ESTIMATION OF OPERATIVE RISK CLINICAL FUNCTIONAL PERIOP. INHERENT SURGICAL PREDICTORS IMPAIRMENT RISK RISK High risk Very limited ADLs HIGH High risk >5% e.g.,unstable or ++++ EST e.g., AAA or cor syndrome - emergent abd.op. Intermediate risk - INTER- Intermediate 1-5% e.g., prior MI - MEDIATE e.g. TURP or Low risk Vigorous ADLs ORIF e.g., stable abn’l or (-) EST at LOW Low risk <1% EKG hight workload. e.g., cataract op.

  5. Energy Requirements –Can Patient Perform 4 Mets?

  6. CARDIAC RISK INDICES (I) The Goldman Index

  7. RISK OF MAJORCARDIAC COMPLICATIONS Class I 0-5 pts. Class II 6-12 pts. Class III 13-25 pts. Class IV =,> 26 pts. Mangano, Goldman et al.

  8. (II) ACC AHA Guide- lines

  9. S S I C C I C Up-to-date

  10. S I C C I C (III)

  11. Indications for pre-op stress testing • EXCLUSIONS: Pts. with likely CAD who will not consent to revascularization procedures. Pts. whose non-cardiac surgery cannot be deferred for 4-6 weeks. • Pts. with recent ACS- MI, Unst.AP, ischemic APE- not revascularized, now asymptomatic, for intermediate or high risk surgery. • Pts. for intermediate or high risk surgery with limited exertional capacity, plus additional clinical risk factors such as CHF, cerebrovascular disease, diabetes, CRI.

  12. Risk Reduction for the Cardiac Patient for Non-cardiac Surgery Choice of procedure Choice of surgeon and hospital Choice of pre-op interventions and meds. Optimization of status in time allotted(?)

  13. Expected post-revascularization delays • CABS-1-3 months convalescence for physical and emotional rehab. • DES- at least 3 months clopidigrel,to reduce instent-thrombosis risk. • BMS- 4-6 weeks clopidigrel. • POBA- one month, for hypercoagulable intima.

  14. 8/56= 14% MACE- IF WITHIN 6 WEEKS OF PCI. Am. J. Cardiol. 2005; 95:755

  15. 510 pts randomized. For expanding AAA or PVD of legs. At incr. clinical risk or ischemia on EST. All had coronary angios with stenosis>70% in one or more major cor. arts. Exclusions: Need for urgent or emergency surgery. LMCAD > 50% LVEF < 20% Severe AS. REVASCULARIZATION 30-day mortality: Revasc-3.1% No Revasc- 3.4% Post-op MI(incr. Trop.)- 12% vs 14% McFalls et al., Coronary-Artery Revascularization before Elective Major Vascular Surgery. NEJM 2004;351:2795-804.

  16. Myoc. O2 Demand during Anesthesia and Surgery . RPP Consent 10,000 On BBs Hosp. O.R. Induction I hr.into Transfer 24 hrs Adm. Arrival of Anesth. Surgery to PACU later Frishman and Oka

  17. Effect of atenolol on mortality and cardiovascular morbidity after noncardiac surgery. Mangano et al, NEJM 1996; 335;1713-20 .

  18. 112 pts., + DSE Bisoprolol 5-10mg po vs P. Begun av. 37 d. pre-op, to 30 d. post-op. Cardiac death 3.4%vs 17% Nonfatal MI 0% vs 17% Cardiacdeath 3.4%vs 17% Nonfatal MI 0% vs 17% 53 pts. on BBs previously - Mortality 4.5% NEJM 1999;341:1789-94

  19. B-Blockers and Reduction of Cardiac Events in Noncardiac Surgery. A.D.Auerbach, MD, MPH and Lee Goldman, MD

  20. PREDICTORS OF CARDIAC EVENTS AFTER MAJOR VASCULAR SURGERY Boersma et al, JAMA 2001:285;1865-1873

  21. Case control study. 2816 pts.- vasc. Surgery- 160 died - each compared to 2 survivors matched by year and surgery. Statin use - in Deaths: 8%. - in Survivors: 25% OR for periop. mortality among statin users vs. nonusers: 0.22 (0.10-0.47)

  22. Grayburn, P.A. and Hillis, L.D., Annals Int. Med. 2003; 138:506-511

  23. IN CONCLUSION….. • Who need B-Blockers? Pts. for intermediate or high risk surgery, with confirmed or likely CAD, or coronary risk factors (without asthma or bradys.) • Who need stress testing?* Pts. with (probable) CAD, for elective intermediate or high risk surgery, with limited exertional capacity, plus additional clinical risk factors such as CHF, CVA/TIA, diabetes, CRI. • Who need coronary angios?* Pts. with recent ACS for intermediate or high risk op. Pts. with extensive ischemia on EST. Pts. with hair-trigger angina despite Rx. * if urgency of surgery permits.

  24. 1. 76 M. for TURP. Had IWMI 5 yrs. ago, with occasional exertional angina since. Is on Imdur. • Inherent surgical risk – 1-3%. • Pt.’s clinical risk - Intermediate. • Exercise tolerance – very good. Condition is stable. • Overall peri-op risk – 2-3 % for peri-op Mortality, M.I., CHF. • Steps to reduce risk: Add B-blocker pre-op. ?Add statins - proper run-in time? Maintain HCT > 30% Add ASA soon post-op.

  25. Qualitative assessment of operative risk CLINICAL FUNCTIONAL PERIOP. INHERENT SURGICAL PREDICTORS IMPAIRMENT RISK RISK High risk Very limited ADLs HIGH High risk >5% e.g.,unstable or ++++ EST e.g., AAA or cor syndrome - emergent abd.op. Intermediate risk - INTER- Intermediate 1-5% e.g., prior MI - MEDIATE e.g. TURP or Low risk Vigorous ADLs ORIF e.g., stable abn’l or (-) EST at LOW Low risk <1% EKG hight workload. e.g., cataract op.

  26. 2. 72 yo W. –acute NSTEMI 2 wks. ago. Has 2 cm. left breast nodule. • Clinical risk intermediate or high, depending on ease of precipitating ischemia. • Surgical risk- low for biopsy - intermediate for mastectomy. • Moderate time pressures for intervention- chiefly emotional: PCI and Plavix x 6 weeks to 3-6 months? CABS and rehab x two months? EST and BB’s in one-two weeks?

  27. 3. 73 yo M. has ischemic rest pain.Also HTN, LVH and angina on Rx.Fem-pop bypass proposed. • Surgical risk- intermediate –to - high. • Clinical risk- Intermediate. • Exercise tolerance – limited by claudication. • Time factor - < 30 days- no gangrene yet. • Options? - BB’s -EST stratification - PCI - CABS • If 2-block claudication w/o rest pain? Med. management or possibly iliac stent. Future CAD risk stratifiction.

  28. 4. 54 yo W. needs hysterectomy, has anemia. Has HTN and NSSTTC. • Surgical risk is intermediate; low if laparoscopic. • Clinical risk low (hypertension) - or - intermediate ( if NSSTTC are significant and new.) • Exercise tolerance very good. • Time factor – not urgent. • Steps: Obtain old EKGs. Start HTN Rx- BB’s, diuretics, ACE-inhibs. Consider EST if duration of STTC is unknown.

  29. 5. 80 yo W., left hip IT fracture x5wks, history of HTN, and atrial fibrillation. • Heart rate control- BB’s, CCB’s, digoxin. • Heart disease assessment – Px, 2DE. Stress testing and revascularization are precluded by the fracture. • Anticoagulation Rx- indicated but not urgent. Long term use will depend on reliability and communication issues. • Orthopedic time frame – elective at this point.

  30. 6. 28 yo W., with click and MVP, requires dental work. • Dx- Mitral valve prolapse, with (perhaps) MR. No arrhythmias or chest pain. • Meds- e.g., Fiorinal PRN, OCPs. Not on A/C Rx. • Allergies- NKDA • Recs: Premedicate with Amoxicillin 2 gms po. Use “EPI” if preferable.

  31. 7. 72 yo M. for TKR, with NIDDM and asymptomatic left carotid stenosis. • Time frame is elective. • Estimate surgical risk as low intermediate. • Exercise tolerance is unknown and CAD likely, but he has no CHF, prior MI,CVA/TIA, insulin use or CRI. DSE or Persantine MIBI are probably not indicated. • Plan for CEA, in view of ACAS data if institutional surgical risk is <5%. • With DM and carotid vasc. disease, considercoronary risk equivalent to that of prior MI with respect to statin, BB, and ASA use

  32. 8. 55. yo W. has mechanical MVR, Atr. Fib, on A/C RX, and needs dental extractions. • Hold Warfarin for 3 nights, check INR and proceed, then immediately resume RX. • Or- Hold A/C RX for 4 nights. Check INR on 3rd day, and cover with LMWH pre-op and immediately post-op, while resuming warfarin. • Remember SBE prophylaxis- Amox or Erythro. or Clinda. • “Epi” is permitted.

More Related